Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...
The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...
A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...
Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT screenings for those eligible – the disease can be completely curable.
At the 2026 Miami Breast Cancer Conference, Kevin Kalinsky, MD, MS, participated in a molecular tumor board session that brought together a multidisciplinary panel including medic ...
NEW ORLEANS - Ochsner MD Anderson Cancer Center will be the first in the South to offer Biology-Guided Radiotherapy, joining ...
A Prescription Drug User Fee Act target date has been set for the third quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results